Is There a Value of Neurofilament Light as a Biomarker for Neurodegeneration in Parkinson's Disease?

Henrik Zetterberg MD, PhD,

Corresponding Author

Henrik Zetterberg MD, PhD

[email protected]

Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

Department of Neurodegenerative Disease, University College London Institute of Neurology, Queen Square, London, United Kingdom

UK Dementia Research Institute at University College London, London, United Kingdom

Correspondence to: Dr. Henrik Zetterberg, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, S-431 80 Mölndal, Sweden; E-mail: [email protected]Search for more papers by this author

Henrik Zetterberg MD, PhD,

Corresponding Author

Henrik Zetterberg MD, PhD

[email protected]

Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

Department of Neurodegenerative Disease, University College London Institute of Neurology, Queen Square, London, United Kingdom

UK Dementia Research Institute at University College London, London, United Kingdom

First published: 21 July 2020

https://doi.org/10.1002/mds.28101

Citations: 6

Relevant conflicts of interests/financial disclosures: H.Z. has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, and CogRx; has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen; and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg.

Read the full text

About

PDF

Tools

Share a link

Email
Facebook
Twitter
LinkedIn
Reddit
Wechat

No abstract is available for this article.

References

1Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996; 67(5): 2013–2018.
10.1046/j.1471-4159.1996.67052013.x
CASPubMedWeb of Science®Google Scholar
2Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003; 987(1): 25–31.
10.1016/S0006-8993(03)03219-0
CASPubMedWeb of Science®Google Scholar
3Bridel C, van Wieringen WN, Zetterberg H, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol 2019; 76(9): 1035–1048.
10.1001/jamaneurol.2019.1534
PubMedWeb of Science®Google Scholar
4Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012; 69(11): 1445–1452.
10.1001/archneurol.2012.1654
PubMedWeb of Science®Google Scholar
5Magdalinou NK, Paterson RW, Schott JM, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2015; 86(11): 1240–1247.
10.1136/jnnp-2014-309562
CASPubMedWeb of Science®Google Scholar
6Hansson O, Janelidze S, Hall S, et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 2017; 88(10): 930–937.
10.1212/WNL.0000000000003680
CASPubMedWeb of Science®Google Scholar
7Marques TM, van Rumund A, Oeckl P, et al. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology 2019; 92(13): e1479–e1486.
10.1212/WNL.0000000000007179
PubMedWeb of Science®Google Scholar
8Lerche S, Wurster I, Roeben B, et al. CSF NFL in a longitudinally assessed PD cohort: age effects and cognitive trajectories. Mov Disord 2020; 35(7): 1138–1144.
10.1002/mds.28056
CASPubMedWeb of Science®Google Scholar
9Wilke C, Teixeira dos Santos MC, Schulte C, et al. Intraindividual neurofilament dynamics in serum mark the conversion to sporadic Parkinson's disease. Mov Disord 2020; 35(7): 1233–1238.
10.1002/mds.28026
CASPubMedWeb of Science®Google Scholar
10Zetterberg H, Bendlin BB. Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies [published online ahead of print April 6, 2020]. Mol Psychiatry. https://doi.org/10.1038/s41380-020-0721-9

Google Scholar
11Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol 2016; 3(10): 812–818.
10.1002/acn3.338
CASPubMedWeb of Science®Google Scholar
12Shahnawaz M, Tokuda T, Waragai M, et al. Development of a biochemical diagnosis of Parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol 2017; 74(2): 163–172.
10.1001/jamaneurol.2016.4547
PubMedWeb of Science®Google Scholar

Citing Literature

Volume35, Issue7

July 2020

Pages 1111-1112

Is There a Value of Neurofilament Light as a Biomarker for Neurodegeneration in Parkinson's Disease?

References

Citing Literature

References

Information

RESOURCES

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Is There a Value of Neurofilament Light as a Biomarker for Neurodegeneration in Parkinson's Disease?

References

Citing Literature

References

Related

Information

RESOURCES